These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32873702)

  • 41. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
    Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
    Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters.
    Kilinç N; Yaldiz M
    Eur J Gynaecol Oncol; 2004; 25(5):606-10. PubMed ID: 15493177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study.
    Martin SE; Temm CJ; Goheen MP; Ulbright TM; Hattab EM
    Mod Pathol; 2011 Oct; 24(10):1320-6. PubMed ID: 21623385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Matrix-producing breast carcinoma with myoepithelial differentiation--description of 11 cases and review of literature aimed at histogenesis and differential diagnosis].
    Kinkor Z; Boudová L; Ryska A; Kajo K; Svec A
    Ceska Gynekol; 2004 May; 69(3):229-36. PubMed ID: 15310000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
    Werling RW; Hwang H; Yaziji H; Gown AM
    Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
    Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.
    Barbareschi M; Caffo O; Doglioni C; Fina P; Marchetti A; Buttitta F; Leek R; Morelli L; Leonardi E; Bevilacqua G; Dalla Palma P; Harris AL
    Br J Cancer; 1996 Jul; 74(2):208-15. PubMed ID: 8688323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
    Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
    Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pleomorphic carcinoma of the breast: clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma.
    Silver SA; Tavassoli FA
    Histopathology; 2000 Jun; 36(6):505-14. PubMed ID: 10849092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
    Li X; Chen X; Wen L; Wang Y; Chen B; Xue Y; Guo L; Liao N
    Thorac Cancer; 2020 Jul; 11(7):1861-1868. PubMed ID: 32412177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.
    O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V
    Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
    Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
    Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.